Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

AdaptHealth Q3 2026 Results: Net Loss of $154M

AdaptHealth Corp. reported a significant net loss of $300.4 million for the nine months ended September 30, 2026, primarily driven by $329.0 million in goodwill impairment charges. Despite the net loss, net revenue grew to $2.17 billion compared to $1.97 billion in the prior year period, while the company also announced plans for the divestiture of its Diabetes Health business.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue745.6672.4
Profit before tax-184.518.0
Net income-154.024.5
EPS (diluted, $ a share)$-1.13$0.17

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+10.9%
Operating margin-20.9%
Source

10-Q filed with the SEC, NASDAQ: AHCO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

AdaptHealth Corp.: key numbers

Share price
$7.53Close, Nov 17
Market cap
$1.03B
Shares outstanding
136.53MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Home Health Care ServicesSIC 8082

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from AdaptHealth Corp.

All →
8:12 AM ET 8-K
Financial Results

AdaptHealth Financial Results

AdaptHealth Corp. reported Q3 2026 net revenue of $745.6 million, a 10.9% increase year-over-year, though it recorded a net loss of $168.2 million primarily due to a $184.8 million goodwill write-down. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance while lowering its free cash flow outlook. Additionally, the company noted progress on the pending $235 million sale of its Diabetes Health business, which cleared the HSR waiting period.

Term
Q3 2026

“In the third quarter, we delivered strong organic revenue growth and exceeded our guidance for revenue, Adjusted EBITDA and free cash flow. Our capitated partnership made a positive contribution to enterprise Adjusted EBITDA, driven by a tighter labor model and lower costs to serve. We also continue to move toward closing the sale of our Diabetes Health business, bringing us closer to a more focused portfolio built around Sleep Health, Respiratory Health and Wellness-at-Home. The business is stabilizing as we work through a period of transformation, and we look forward to carrying that momentum into 2027.”

Suzanne Foster, Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.